Related Experiment Video
Updated: Sep 15, 2025

Using Multi-fluorinated Bile Acids and In Vivo Magnetic Resonance Imaging to Measure Bile Acid Transport
Published on: November 27, 2016
Changes in Serum Bilirubin and Total Bile Acids During Biologic Therapy in Patients with Ulcerative Colitis: A
Zhengyu Ren1, Zhewei Zhang2, Haichen Li1
1Department of Gastroenterology, First Affiliated Hospital, Xi'an Jiaotong University, Shaanxi, People's Republic of China.
Purpose:
Ulcerative colitis (UC) requires new non-invasive serum biomarkers for assistance in monitoring due to the low rate of endoscopic follow-up. Previous research indicated reduced levels of serum indirect bilirubin (sIBIL), serum total bilirubin (sTBIL), and serum total bile acids (sTBAs) in UC patients. This study aims to assess their monitoring potential in UC during biologic therapy.
Methods:
We conducted a retrospective single-center study including 138 UC patients and 150 controls with normal colonoscopy results. The receiver operating characteristic (ROC) curve was used to assess diagnostic value of sIBIL, sTBIL, and sTBAs. Spearman correlation analysis was performed to assess the association between these biomarkers and the severity of both endoscopic findings and clinical symptoms in UC patients. Additionally, changes in serum biomarkers were analyzed in 72 UC patients during biologic therapy, with stratified analyses based on endoscopic remission status.
Results:
Patients with UC exhibited lower concentrations of sIBIL, sTBIL, and sTBAs compared to the controls (P < 0.05), and all these biomarkers demonstrated moderate diagnostic value in identifying UC from normal controls (P < 0.05). sIBIL concentration negatively correlated with disease severity and showed a progressive increase during biologic therapy, particularly in patients achieving endoscopic remission at week 52 (P < 0.05). The sIBIL concentration in the remission group was significantly higher than that in the non-remission group after week 26 (P < 0.05). For sTBAs, concentration initially increased and then decreased, with a turning point at week 14 in the remission group (P < 0.05) and at week 26 in the non-remission group (P > 0.05). No significant differences in sTBAs concentrations were found between remission and non-remission groups at any time (P > 0.05).
Conclusion:
sIBIL may be used as a valuable serum biomarker for the clinical diagnosis and the monitoring of response to biologics. Additionally, the change trend of sTBAs may provide reference value for monitoring UC biologic therapy. However, further studies are needed to analyze the changes in its internal composition.
Related Concept Videos
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

